title: Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline.
abstract: Doxycycline is a tetracycline that has been licensed for veterinary use in some countries, but no clinical breakpoints are available for veterinary pathogens. The objectives of this study were (i) to establish breakpoints for doxycycline and (ii) to evaluate the use of tetracycline as a surrogate to predict the doxycycline susceptibility of Staphylococcus pseudintermedius isolates. MICs and inhibition zone diameters were determined for 168 canine S. pseudintermedius isolates according to Clinical and Laboratory Standards Institute (CLSI) standards. Tetracycline resistance genes were detected by PCR, and time-kill curves were determined for representative strains. In vitro pharmacodynamic and target animal pharmacokinetic data were analyzed by Monte Carlo simulation (MCS) for the development of MIC interpretive criteria. Optimal zone diameter breakpoints were defined using the standard error rate-bounded method. The two drugs displayed bacteriostatic activity and bimodal MIC distributions. Doxycycline was more active than tetracycline in non-wild-type strains. MCS and target attainment analysis indicated a certainty of ≥ 90% for attaining an area under the curve (AUC)/MIC ratio of >25 with a standard dosage of doxycycline (5 mg/kg of body weight every 12 h) for strains with MICs of ≤ 0.125 μg/ml. Tetracycline predicted doxycycline susceptibility, but current tetracycline breakpoints were inappropriate for the interpretation of doxycycline susceptibility results. Accordingly, canine-specific doxycycline MIC breakpoints (susceptible, ≤ 0.125 μg/ml; intermediate, 0.25 μg/ml; resistant, ≥ 0.5 μg/ml) and zone diameter breakpoints (susceptible, ≥ 25 mm; intermediate, 21 to 24 mm; resistant, ≤ 20 mm) and surrogate tetracycline MIC breakpoints (susceptible, ≤ 0.25 μg/ml; intermediate, 0.5 μg/ml; resistant, ≥ 1 μg/ml) and zone diameter breakpoints (susceptible, ≥ 23 mm; intermediate, 18 to 22 mm; resistant, ≤ 17 mm) were proposed based on the data generated in this study.
authors: Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark.
authors: Marit Gaastra
authors: MG
authors: Maaland
authors: Mark G
authors: MG
authors: Papich
authors: John
authors: J
authors: Turnidge
authors: Luca
authors: L
authors: Guardabassi
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004283:Dog Diseases / Q000188:drug therapy / Q000382:microbiology; D004285:Dogs; D004318:Doxycycline / Q000493:pharmacokinetics* / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D008962:Models, Theoretical; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D013210:Staphylococcus / Q000187:drug effects*; D013752:Tetracycline / Q000493:pharmacokinetics* / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D013752:Tetracycline; D004318:Doxycycline
references: Vet Microbiol. 1998 Oct;63(2-4):217-27
references: 9851000
references: Vet Dermatol. 2012 Aug;23(4):253-66, e51-2
references: 22515504
references: J Antimicrob Chemother. 2008 Mar;61(3):621-8
references: 18252694
references: Clin Microbiol Rev. 2007 Jul;20(3):391-408, table of contents
references: 17630331
references: J Antimicrob Chemother. 2011 Feb;66(2):227-31
references: 21118912
references: J Antimicrob Chemother. 2006 Aug;58(2):256-65
references: 16816396
references: Clin Microbiol Infect. 2000 May;6(5):270-3
references: 11168126
references: J Vet Med B Infect Dis Vet Public Health. 2005 Feb;52(1):25-31
references: 15702997
references: Am J Vet Res. 2013 Jan;74(1):130-5
references: 23270357
references: J Antimicrob Chemother. 2003 Aug;52(2):145-8
references: 12837738
references: J Vet Pharmacol Ther. 1990 Dec;13(4):415-24
references: 2287034
references: J Am Acad Dermatol. 2006 Feb;54(2):258-65
references: 16443056
references: Vet Microbiol. 2013 Mar 23;162(2-4):968-971
references: 23107659
references: Diagn Microbiol Infect Dis. 2013 May;76(1):69-72
references: 23490012
references: Vet Microbiol. 2012 Mar 23;155(2-4):284-90
references: 21925810
references: J Antimicrob Chemother. 2011 Feb;66(2):343-9
references: 20926397
references: Acta Vet Scand. 2012 Jun 08;54:35
references: 22682068
references: Antimicrob Agents Chemother. 1996 Jan;40(1):1-5
references: 8787868
references: J Clin Microbiol. 2010 Mar;48(3):765-9
references: 20053855
references: Aust Vet J. 2006 Jan-Feb;84(1-2):8-11
references: 16498827
references: FEMS Microbiol Rev. 1996 Oct;19(1):1-24
references: 8916553
references: J Appl Microbiol. 2007 Nov;103(5):2016-25
references: 17953612
references: J Clin Microbiol. 2009 Feb;47(2):469-71
references: 19091817
references: Antimicrob Agents Chemother. 2008 Jun;52(6):2156-62
references: 18411321
references: Antimicrob Agents Chemother. 1975 Dec;8(6):713-20
references: 1211925
references: Am J Vet Res. 2003 Aug;64(8):1040-6
references: 12926599
references: Zentralbl Bakteriol. 1994 Nov;281(4):526-33
references: 7727901
references: Microb Drug Resist. 2009 Mar;15(1):55-9
references: 19216647
references: Pharmacotherapy. 2006 Jan;26(1):129-34
references: 16506354
references: Diagn Microbiol Infect Dis. 2000 Jun;37(2):127-37
references: 10863107
references: Chemotherapy. 1971;16(4):217-28
references: 4941358
references: J Antimicrob Chemother. 2005 May;55(5):601-7
references: 15772142
references: Antimicrob Agents Chemother. 2012 Jun;56(6):2795-805
references: 22371890
references: Can J Vet Res. 1988 Jan;52(1):12-4
references: 3349389
references: Clin Microbiol Infect. 2006 May;12(5):418-25
references: 16643517
references: Tijdschr Diergeneeskd. 1988 Nov 1;113(21):1189-93
references: 3187973
references: Microbiol Mol Biol Rev. 2001 Jun;65(2):232-60 ; second page, table of contents
references: 11381101